(Q34679230)

3 August 2017

1 reference

title

The relationship between oxidative/nitrative stress and pathological inclusions in Alzheimer's and Parkinson's diseases (English)

1 reference

3 August 2017

0 references

1 reference

4

John Q Trojanowski

1 reference

3 August 2017

Benoit I Giasson

1

1 reference

PubMed ID

12057764

3 August 2017

Harry Ischiropoulos

series ordinal

2

1 reference

PubMed ID

12057764

3 August 2017

Virginia M-Y Lee

series ordinal

3

1 reference

3 August 2017

1 June 2002

1 reference

Free Radical Biology and Medicine

3 August 2017

1 reference

3 August 2017

32

1 reference

3 August 2017

1264-1275

1 reference

3 August 2017

12

1 reference

Free radical theory of aging

3 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Oxidants, antioxidants, and the degenerative diseases of aging

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Protein oxidation and aging

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Reactions of oxyl radicals with DNA.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Assays of oxidative DNA damage biomarkers 8-oxo-2'-deoxyguanosine and 8-oxoguanine in nuclear DNA and biological fluids by high-performance liquid chromatography with electrochemical detection

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Determination of 8-hydroxydeoxyguanosine by an immunoaffinity chromatography-monoclonal antibody-based ELISA.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Assay of excised oxidative DNA lesions: isolation of 8-oxoguanine and its nucleoside derivatives from biological fluids with a monoclonal antibody column

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Derivatization of gamma-glutamyl semialdehyde residues in oxidized proteins by fluoresceinamine

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Oxidative damage to proteins: spectrophotometric method for carbonyl assay

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Role of nonenzymatic glycosylation in atherogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Glucose autoxidation and protein modification. The potential role of 'autoxidative glycosylation' in diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Formation pathways for lysine-arginine cross-links derived from hexoses and pentoses by Maillard processes: unraveling the structure of a pentosidine precursor

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Advanced Maillard reaction end products are associated with Alzheimer disease pathology

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Advanced glycation end products in Alzheimer's disease and other neurodegenerative diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Glycoxidation and oxidative stress in Parkinson disease and diffuse Lewy body disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Identification of 4-hydroxynonenal as a cytotoxic product originating from the peroxidation of liver microsomal lipids

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Histochemical detection of 4-hydroxynonenal protein in Alzheimer amyloid.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Measurement of lipid peroxidation

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

The reaction of no with superoxide

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Nitric oxide synthases in mammals

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Oxidative DNA damage induced by simultaneous generation of nitric oxide and superoxide

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Peroxynitrite causes DNA nicks in plasmid pBR322

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

DNA strand breakage, activation of poly (ADP-ribose) synthetase, and cellular energy depletion are involved in the cytotoxicity of macrophages and smooth muscle cells exposed to peroxynitrite

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Peroxynitrite-induced membrane lipid peroxidation: the cytotoxic potential of superoxide and nitric oxide

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Peroxynitrite-mediated oxidative protein modifications

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Aromatic hydroxylation and nitration of phenylalanine and tyrosine by peroxynitrite. Evidence for hydroxyl radical production from peroxynitrite

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Immunohistochemical methods to detect nitrotyrosine

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Antibodies that recognize nitrotyrosine

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Formation of reactive nitrogen species during peroxidase-catalyzed oxidation of nitrite. A potential additional mechanism of nitric oxide-dependent toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Dityrosine cross-linking promotes formation of stable alpha -synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Mass spectrometric quantification of 3-nitrotyrosine, ortho-tyrosine, and o,o'-dityrosine in brain tissue of 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-treated mice, a model of oxidative stress in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Phosphorylation of paired helical filament tau in Alzheimer's disease neurofibrillary lesions: focusing on phosphatases

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Autopsy samples of Alzheimer's cortex show increased peroxidation in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Selective increase in lipid peroxidation in the inferior temporal cortex in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Increased peroxidation and reduced antioxidant enzyme activity in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Brain membrane fluidity and lipid peroxidation in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Increased susceptibility of Alzheimer's disease temporal cortex to oxygen free radical-mediated processes.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Evidence against the involvement of reactive oxygen species in the pathogenesis of neuronal death in down's syndrome and Alzheimer's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

An assessment of oxidative damage to proteins, lipids, and DNA in brain from patients with Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Elevated 4-hydroxynonenal in ventricular fluid in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

In Alzheimer's disease, heme oxygenase is coincident with Alz50, an epitope of tau induced by 4-hydroxy-2-nonenal modification.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Isoprostanes. Novel markers of endogenous lipid peroxidation and potential mediators of oxidant injury

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Increased CSF F2-isoprostane concentration in probable AD.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Cerebrospinal fluid F2-isoprostane levels are increased in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Increased F2-isoprostanes in Alzheimer's disease: evidence for enhanced lipid peroxidation in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Widespread peroxynitrite-mediated damage in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Electrochemical analysis of protein nitrotyrosine and dityrosine in the Alzheimer brain indicates region-specific accumulation.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Increased nuclear DNA oxidation in the brain in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

RNA oxidation is a prominent feature of vulnerable neurons in Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Oxidative damage to DNA in lymphocytes from AD patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Direct evidence of oxidative injury produced by the Alzheimer's beta-amyloid peptide (1-40) in cultured hippocampal neurons

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

A model for beta-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: relevance to Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Hydrogen peroxide mediates amyloid beta protein toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

beta-Amyloid-induced toxicity in rat hippocampal cells: in vitro evidence for the involvement of free radicals

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Amyloid-β Deposition in Alzheimer Transgenic Mice Is Associated with Oxidative Stress

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Inflammation and Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Prevalence of parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Pathophysiology of the basal ganglia in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

The absolute number of nerve cells in substantia nigra in normal subjects and in patients with Parkinson's disease estimated with an unbiased stereological method

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Neuropathology of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Amygdala pathology in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Mutation in the alpha-synuclein gene identified in families with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Alpha-synuclein in Lewy bodies

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Accumulation of alpha-synuclein/NACP is a cytopathological feature common to Lewy body disease and multiple system atrophy.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain alpha-synuclein immunoreactivity.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

The oxidative metabolism of catecholamines in the brain: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Autoxidation and Neurotoxicity of 6-Hydroxydopamine in the Presence of Some Antioxidants

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Increased nigral iron content in postmortem parkinsonian brain.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Neuromelanin-containing neurons of the substantia nigra accumulate iron and aluminum in Parkinson's disease: a LAMMA study

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Protein nitration in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Crosslinking of alpha-synuclein by advanced glycation endproducts--an early pathophysiological step in Lewy body formation?

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Positron emission tomography after MPTP: observations relating to the cause of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Toxicity of MPTP and structural analogs in clonal cell lines of neuronal origin expressing B type monoamine oxidase activity

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Localization of distinct monoamine oxidase a and monoamine oxidase b cell populations in human brainstem

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Absence of MPTP-induced neuronal death in mice lacking the dopamine transporter.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Evidence that the inhibition sites of the neurotoxic amine 1-methyl-4-phenylpyridinium (MPP+) and of the respiratory chain inhibitor piericidin A are the same

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Inhibition of mitochondrial NADH dehydrogenase by pyridine derivatives and its possible relation to experimental and idiopathic parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

1-Methyl-4-phenylpyridinium (MPP+) induces NADH-dependent superoxide formation and enhances NADH-dependent lipid peroxidation in bovine heart submitochondrial particles

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

The parkinsonism-inducing drug 1-methyl-4-phenylpyridinium triggers intracellular dopamine oxidation. A novel mechanism of toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Manganese superoxide dismutase overexpression attenuates MPTP toxicity.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Inhibition of neuronal nitric oxide synthase by 7-nitroindazole protects against MPTP-induced neurotoxicity in mice.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Inhibition of neuronal nitric oxide synthase prevents MPTP-induced parkinsonism in baboons.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Inhibition of neuronal nitric oxide synthase protects against MPTP toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Deficiency of inducible nitric oxide synthase protects against MPTP toxicity in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

MPP+ induced substantia nigra degeneration is attenuated in nNOS knockout mice

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Inactivation of tyrosine hydroxylase by nitration following exposure to peroxynitrite and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Chronic systemic pesticide exposure reproduces features of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Generation of superoxide anion by the NADH dehydrogenase of bovine heart mitochondria

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Convergence of Lewy bodies and neurofibrillary tangles in amygdala neurons of Alzheimer's disease and Lewy body disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Occurrence of human alpha-synuclein immunoreactive neurons with neurofibrillary tangle formation in the limbic areas of patients with Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Antibodies to alpha-synuclein detect Lewy bodies in many Down's syndrome brains with Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Alpha-synuclein inclusions in amygdala in the brains of patients with the parkinsonism-dementia complex of Guam

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Parkinson disease, dementia, and Alzheimer disease: clinicopathological correlations.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Neuropathologic and clinical features of Parkinson's disease in Alzheimer's disease patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Dementia in idiopathic Parkinson's disease. A neuropathological study of 32 cases.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Dementia in Parkinson disease: A neuropathologic study

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Diffuse intracytoplasmic ganglionic inclusions (Lewy type) associated with progressive dementia and quadriparesis in flexion

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Quantitative neuropathological study of Alzheimer-type pathology in the hippocampus: Comparison of senile dementia of Alzheimer type, senile dementia of Lewy body type, Parkinson's disease and non-demented elderly control patients

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Alzheimer's disease and Lewy body disease: a comparative clinicopathological study.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Dementia with Lewy bodies: a pure case.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Diffuse Lewy body disease: light and electron microscopic immunocytochemistry of senile plaques.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Clinical and quantitative pathologic correlates of dementia with Lewy bodies.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

The Lewy body variant of Alzheimer's disease: a clinical and pathologic entity

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Genetic evidence that the Lewy body variant is indeed a phenotypic variant of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Neocortical lewy body counts correlate with dementia in the Lewy body variant of Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Oxidative damage to proteins, lipids, and DNA in cortical brain regions from patients with dementia with Lewy bodies.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

The nosology of Hallervorden-spatz disease

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Hallervorden-Spatz syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Homozygosity mapping of Hallervorden-Spatz syndrome to chromosome 20p12.3-p13

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Lewy body in neurodegeneration with brain iron accumulation type 1 is immunoreactive for alpha-synuclein.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Alpha-synuclein immunoreactivity is present in axonal swellings in neuroaxonal dystrophy and acute traumatic brain injury

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Neurodegeneration with brain iron accumulation, type 1 is characterized by alpha-, beta-, and gamma-synuclein neuropathology

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Widespread occurrence of alpha-synuclein/NACP-immunoreactive neuronal inclusions in juvenile and adult-onset Hallervorden-Spatz disease with Lewy bodies

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Widespread expression of alpha-synuclein and tau immunoreactivity in Hallervorden-Spatz syndrome with protracted clinical course

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

A Drosophila model of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Neuropathology in mice expressing human alpha-synuclein

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Age-Dependent Emergence and Progression of a Tauopathy in Transgenic Mice Overexpressing the Shortest Human Tau Isoform

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Effects of the mutations Ala30 to Pro and Ala53 to Thr on the physical and morphological properties of alpha-synuclein protein implicated in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Mutant and wild type human alpha-synucleins assemble into elongated filaments with distinct morphologies in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Widespread nitration of pathological inclusions in neurodegenerative synucleinopathies

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Distinctive neuropathology revealed by α-synuclein antibodies in hereditary parkinsonism and dementia linked to chromosome 4p

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Accumulation of Insoluble α-Synuclein in Dementia with Lewy Bodies

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Non-Abeta component of Alzheimer's disease amyloid (NAC) revisited. NAC and alpha-synuclein are not associated with Abeta amyloid.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Widespread alterations of alpha-synuclein in multiple system atrophy

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Immunohistochemical and biochemical studies demonstrate a distinct profile of alpha-synuclein permutations in multiple system atrophy

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Assembly of Alzheimer-like filaments from full-length tau protein.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Alzheimer-like paired helical filaments and antiparallel dimers formed from microtubule-associated protein tau in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Oxidation of cysteine-322 in the repeat domain of microtubule-associated protein tau controls the in vitro assembly of paired helical filaments

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Assembly of microtubule-associated protein tau into Alzheimer-like filaments induced by sulphated glycosaminoglycans.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

RNA stimulates aggregation of microtubule-associated protein tau into Alzheimer-like paired helical filaments

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

A nucleated assembly mechanism of Alzheimer paired helical filaments

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Oxidative regulation of fatty acid-induced tau polymerization.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Alpha-tocopherol and Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

The effect of deprenyl and tocopherol on cognitive performance in early untreated Parkinson's disease. Parkinson Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Parkinson Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

The prevalence of the neuropathological lesions of Alzheimer's disease is independent of race and gender

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Existing data suggest that Alzheimer's disease is preventable.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

In vivo detection of amyloid plaques in a mouse model of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Visualization of fibrillar amyloid deposits in living, transgenic Caenorhabditis elegans animals using the sensitive amyloid dye, X-34.

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse

1 reference

https://api.crossref.org/works/10.1016%2FS0891-5849%2802%2900804-3

7 January 2021

10.1016/S0891-5849(02)00804-3

Identifiers

DOI

1 reference

3 August 2017

1 reference

PubMed ID

12057764